Compare VTRS & DRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | DRI |
|---|---|---|
| Founded | 1961 | 1968 |
| Country | United States | United States |
| Employees | 30000 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 22.2B |
| IPO Year | 2019 | 2000 |
| Metric | VTRS | DRI |
|---|---|---|
| Price | $16.21 | $212.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 25 |
| Target Price | $13.50 | ★ $226.50 |
| AVG Volume (30 Days) | ★ 8.9M | 1.2M |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.21% | 3.06% |
| EPS Growth | N/A | ★ 4.11 |
| EPS | 0.15 | ★ 6.87 |
| Revenue | ★ $14,299,900,000.00 | $12,076,700,000.00 |
| Revenue This Year | $4.41 | $10.58 |
| Revenue Next Year | $1.96 | $3.73 |
| P/E Ratio | $106.97 | ★ $30.96 |
| Revenue Growth | N/A | ★ 6.03 |
| 52 Week Low | $8.63 | $169.00 |
| 52 Week High | $17.53 | $222.56 |
| Indicator | VTRS | DRI |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 60.76 |
| Support Level | $16.02 | $187.10 |
| Resistance Level | $16.54 | $212.37 |
| Average True Range (ATR) | 0.49 | 6.09 |
| MACD | -0.01 | 0.51 |
| Stochastic Oscillator | 74.29 | 72.02 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Darden Restaurants is the largest global full-service dining operator, with over $12 billion in system sales across 2,159 company-owned stores at the end of fiscal 2025, spanning the US and Canada. The firm operates 10 banners in four segments, including Olive Garden (43% of sales), LongHorn Steakhouse (25%), and fine dining (21%), which includes The Capital Grille, Ruth's Chris, and Eddie V's. The other 11% of sales comes from smaller concepts such as Yard House and Cheddar's. Darden primarily generates revenue through sales of food and beverage items at its company-owned restaurants. It also earns royalties on sales from 154 franchised locations in US and international markets, which sit within the other segment but are immaterial to consolidated results.